Michael Koch
Endocrinology, Diabetes & Metabolism · Roanoke, VANPI 1558355719
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $39,678 of the $54,877 with a category attached, or 72.3%. Novo Nordisk accounts for 60.4% of it on its own, with 38 other manufacturers making up the rest. Reporting peaked in 2019 at $41,370 and has fallen 99.9% since, to $21 in 2025. Among endocrinology, diabetes & metabolism clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 534 payments — averaging $102.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$33K
- AbbVie$10K
- Johnson & Johnson$5K
- Dexcom, Inc.$953
- Abbott$781
- Medtronic$772
- plus $4K from 33 others
What the payments were for
- Speaking & faculty fees$39,67872%
- Travel & lodging$6,69912%
- Food & beverage$8,48615%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 91 | $33,144 |
| AbbVie | 40 | $9,766 |
| Johnson & Johnson | 17 | $5,387 |
| Dexcom, Inc. | 52 | $953 |
| Abbott | 51 | $781 |
| Medtronic(2 entities) | 24 | $772 |
| Amgen(2 entities) | 46 | $719 |
| Lilly USA, LLC | 27 | $361 |
| AstraZeneca(2 entities) | 19 | $298 |
| Boehringer Ingelheim | 18 | $290 |
| Amarin Pharma, Inc. | 15 | $253 |
| Tandem Diabetes Care, Inc. | 18 | $235 |
| Sanofi-aventis U.S. LLC | 11 | $161 |
| Radius Health, Inc. | 8 | $154 |
| Mannkind Corporation | 9 | $150 |
| Corcept Therapeutics | 8 | $144 |
| Xeris Pharmaceuticals, Inc. | 9 | $121 |
| IBSA Pharma Inc. | 5 | $114 |
| Merck | 9 | $113 |
| Antares Pharma, Inc. | 7 | $102 |
| Bayer | 4 | $85 |
| Insulet Corporation | 6 | $84 |
| Esperion Therapeutics, Inc. | 5 | $81 |
| Eisai Inc. | 4 | $77 |
| Embecta Corp. | 2 | $69 |
| Amneal Pharmaceuticals LLC | 4 | $67 |
| Tersera Therapeutics LLC | 2 | $57 |
| Novartis | 3 | $51 |
| Clarus Therapeutics Inc. | 4 | $45 |
| Ascendis Pharma Endocrinology Inc | 2 | $40 |
| BD | 2 | $35 |
| Kowa Pharmaceuticals America, Inc. | 3 | $35 |
| Ultragenyx Pharmaceutical Inc. | 2 | $29 |
| Gilead | 1 | $26 |
| Nestle Healthcare Nutrition Inc. | 2 | $25 |
| Recordati_rare_diseases_inc. | 1 | $17 |
| Strongbridge US Inc. | 1 | $13 |
| Shire North American Group Inc | 1 | $12 |
| Endo Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tresiba$19,164
- Ozempic$9,834
- Synthroid$8,521
- INVOKANA$5,183
- Xultophy 100/3.6$1,755
- Minimed 670G System$267
- RYBELSUS$230
- InPen$109
- DEXCOM G6 TRANSMITTER$103
How this compares
$54,877 in reported general payments places this provider in the 90th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 22 | $192 |
| Metoprolol Succinate | 12 | $133 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $67 | $19222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Roanoke
- James MulindaRoanoke$788K
- Dewey BaileyRoanoke$645K
- Carl BivensRoanoke$14K
- Farhad ZangenehSterling$1.2M
- Jeffrey SicatGlen Allen$657K
- Domenica RubinoArlington$608K
- Samamtha HudsonMidlothian$372K
- Elias SirajNorfolk$316K
- Allen BurrisPowhatan$261K
- Samim EnayatFairfax$217K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.